Globus Medical, Inc.
GMED · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.60 | -1.16 | 1.42 | 1.15 |
| FCF Yield | 3.61% | 2.74% | 1.40% | 3.02% |
| EV / EBITDA | 23.18 | 17.54 | 24.03 | 26.74 |
| Quality | ||||
| ROIC | 2.92% | 2.10% | 9.29% | 7.83% |
| Gross Margin | 58.90% | 65.05% | 74.22% | 75.03% |
| Cash Conversion Ratio | 5.06 | 1.98 | 0.94 | 1.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.05% | 17.86% | 9.04% | 6.85% |
| Free Cash Flow Growth | 145.25% | 58.23% | -52.40% | 62.34% |
| Safety | ||||
| Net Debt / EBITDA | -0.52 | 0.15 | -0.47 | -0.73 |
| Interest Coverage | 39.63 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.57 | 0.65 | 0.88 | 1.01 |
| Cash Conversion Cycle | 289.68 | 644.48 | 441.38 | 391.22 |